TY - JOUR
T1 - Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas
AU - Hidalgo, Manuel
AU - Von Hoff, Daniel D.
PY - 2012/8/15
Y1 - 2012/8/15
N2 - Pancreatic ductal adenocarcinoma (PDA) remains a devastating disease with nearly equal incidence and mortality rates. Over the past few decades, a litany of randomized clinical trials has failed to improve the outcome of this disease. More recently, the combination chemotherapy regimen FOLFIRINOX has shown improvement in overall survival over the single agent gemcitabine, and nab-paclitaxel (an albumin-coated formulation of paclitaxel) in combination with gemcitabine has shown promising results in phase II studies. Despite limited impact on patient care as of yet, the molecular and biologic understanding of PDA has advanced substantially. This includes understanding the genomic complexity of the disease, the potential importance of the tumor microenvironment, the metabolic adaptation of PDA cells to obtain nutrients in a hypoxic environment, and the role of pancreatic cancer stem cells. These fundamental discoveries are starting to be translated into clinical studies. In this overview, we discuss the implications of biologic understanding of PDA in clinical research and provide insights for future development of novel approaches and agents in this disease.
AB - Pancreatic ductal adenocarcinoma (PDA) remains a devastating disease with nearly equal incidence and mortality rates. Over the past few decades, a litany of randomized clinical trials has failed to improve the outcome of this disease. More recently, the combination chemotherapy regimen FOLFIRINOX has shown improvement in overall survival over the single agent gemcitabine, and nab-paclitaxel (an albumin-coated formulation of paclitaxel) in combination with gemcitabine has shown promising results in phase II studies. Despite limited impact on patient care as of yet, the molecular and biologic understanding of PDA has advanced substantially. This includes understanding the genomic complexity of the disease, the potential importance of the tumor microenvironment, the metabolic adaptation of PDA cells to obtain nutrients in a hypoxic environment, and the role of pancreatic cancer stem cells. These fundamental discoveries are starting to be translated into clinical studies. In this overview, we discuss the implications of biologic understanding of PDA in clinical research and provide insights for future development of novel approaches and agents in this disease.
UR - http://www.scopus.com/inward/record.url?scp=84865062750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865062750&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-12-1327
DO - 10.1158/1078-0432.CCR-12-1327
M3 - Review article
C2 - 22896691
AN - SCOPUS:84865062750
SN - 1078-0432
VL - 18
SP - 4249
EP - 4256
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 16
ER -